Bli medlem
Bli medlem

Du är här

2016-11-18

Active Biotech: Prospectus relating to Active Biotech's rights issue published

2016-11-18NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE
UNLAWFUL.
The prospectus relating to Active Biotech AB's (publ) rights issue has now
been published and is available on the company's website,
www.activebiotech.com. The prospectus can also be ordered from Active Biotech
by telephone +46 (0)46 19 20 00.

For further information, please contact:

Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail:hans.kolam@activebiotech.com

Active Biotech AB

P.O. Box 724, SE-220 07 Lund, Sweden
Phone +46 (0)46 19 20 00
Fax +46 (0)46 19 11 05

Active Biotech AB (publ)

(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally
administered small molecule with unique immunomodulatory properties, is in
pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod och SILC
projects. Please visit www.activebiotech.com for more information.

Important information

This press release is not an offer to subscribe for shares in Active Biotech
and investors should not subscribe for or purchase any securities, except on
the basis of information provided in the prospectus.

This press release may not be made public, released or distributed, directly
or indirectly, in or into the United States, Australia, Japan or Canada or in
any other jurisdiction in which the distribution of this press release would
be unlawful. Further, this press release does not constitute an offer to sell
new shares, interim shares ("BTA") or subscription rights to any person in
any jurisdiction in which it is unlawful to make such offer to such person or
where such action would require additional prospectuses, registration or
other measures other than those pursuant to Swedish law. The prospectus,
application form and other documents associated with the rights issue may not
be distributed in or to any country where such distribution or the rights
issue would require such measures set forth in the preceding sentence or be
in violation of the regulations of such country.

The new shares and subscription rights have not been recommended or approved
by any United States federal or state securities commission or regulatory
authority. No new shares, BTA, subscription rights or other securities issued
by Active Biotech have been or will be registered under the U.S. Securities
Act of 1933, as amended, or under the securities legislation in any state of
the United States, and may not be offered, exercised or sold in the United
States absent registration or an applicable exemption from registration
requirements. There is no intention to register any portion of the rights
issue in the United States or to conduct a public offering of securities in
the United States.

The Company has not authorized any offer of the securities referred to herein
to the public in any country in the European Economic Area ("EEA") other than
Sweden. In other member states in the EEA, the securities may only be offered
to (a) any legal entity which is a qualified investor as defined in the
Directive 2003/71/EC (the "Prospectus Directive"); or (b) any person falling
within Article 3(2) of the Prospectus Directive.

In the United Kingdom, this communication is only being distributed to, and is
only directed at "qualified investors" (as defined in section 86(7) of the
Financial Services and Markets Act 2000) who are (i) investment professionals
falling within the meaning of Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii)
persons falling within Article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc.") of the Order (all such persons together
being referred to as "relevant persons"). In the United Kingdom, any
investment or investment activity to which this communication relates is
available only to, and will be engaged in only with, relevant persons. Any
person who is not a relevant person should not take any action on the basis
of this communication and should not act or rely on it or any of its
contents.
161118_Prospectus relating to Active Biotech's rights issue published
http://hugin.info/1002/R/2057735/771080.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.